TD Cowen & Evercore ISI Praise “Compelling” EDIT-401 Data as Editas Eyes 2026 Human Trials

Editas’ gene therapy EDIT-401 cut bad cholesterol ~90% in animals; analysts bullish; human trials expected in 2026.